PMID- 29792286
OWN - NLM
STAT- MEDLINE
DCOM- 20190124
LR  - 20190124
IS  - 0151-9638 (Print)
IS  - 0151-9638 (Linking)
VI  - 145
IP  - 6-7
DP  - 2018 Jun-Jul
TI  - [Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: A 
      retrospective survey of 102 patients].
PG  - 395-404
LID - S0151-9638(18)30416-2 [pii]
LID - 10.1016/j.annder.2018.03.168 [doi]
AB  - AIM: Our aim was to assess the prevalence of adverse effects (AEs) pertaining to 
      the use and withdrawal of hydroxychloroquine (HCQ) in dermatological outpatients. 
      PATIENTS AND METHODS: We conducted a retrospective study between January 2013 and 
      June 2014 that included consecutive patients currently or previously receiving 
      HCQ seen in our department. AEs were collated using a standardized questionnaire 
      and validated by clinical and laboratory examination. Drug causality was 
      evaluated using the updated French drug reaction causality assessment method. The 
      main evaluation criterion was the prevalence of AEs in which HCQ had an intrinsic 
      imputability score of I>2. RESULTS: We included 102 patients (93 of whom were 
      women, with a median age of 44.5; range: 22-90years). HCQ was given for cutaneous 
      lupus in most cases (n=70). At least one AE was reported for 55 patients. Among 
      the 91 reported AEs, 59 (65%) had an HCQ intrinsic imputability score I>2. AEs 
      were responsible for permanent HCQ discontinuation in 19 cases. Of these, 8 were 
      unrelated to HCQ based on imputability score. The most common AEs associated with 
      HCQ were gastrointestinal and cutaneous signs. Of the 8 patients diagnosed with 
      retinopathy, only 3 were confirmed after reevaluation. CONCLUSION: AEs associated 
      with HCQ were reported for over 50% of patients and were responsible for 
      permanent HCQ discontinuation in one-third of cases. A more in-depth evaluation 
      of imputability seems necessary, particularly regarding ophthalmological 
      symptoms, since in two thirds of cases the reasons for discontinuation were not 
      related to HCQ.
CI  - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.
FAU - Tetu, P
AU  - Tetu P
AD  - Service de dermatologie et allergologie, faculte de medecine, Sorbonne 
      universite, hopital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris cedex 20, 
      France.
FAU - Hamelin, A
AU  - Hamelin A
AD  - Service de dermatologie et allergologie, faculte de medecine, Sorbonne 
      universite, hopital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris cedex 20, 
      France.
FAU - Lebrun-Vignes, B
AU  - Lebrun-Vignes B
AD  - Centre regional de pharmacovigilance, groupe hospitalier Pitie-Salpetriere, 
      AP-HP, 75013 Paris, France.
FAU - Soria, A
AU  - Soria A
AD  - Service de dermatologie et allergologie, faculte de medecine, Sorbonne 
      universite, hopital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris cedex 20, 
      France.
FAU - Barbaud, A
AU  - Barbaud A
AD  - Service de dermatologie et allergologie, faculte de medecine, Sorbonne 
      universite, hopital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris cedex 20, 
      France.
FAU - Frances, C
AU  - Frances C
AD  - Service de dermatologie et allergologie, faculte de medecine, Sorbonne 
      universite, hopital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris cedex 20, 
      France.
FAU - Chasset, F
AU  - Chasset F
AD  - Service de dermatologie et allergologie, faculte de medecine, Sorbonne 
      universite, hopital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris cedex 20, 
      France. Electronic address: francois.chasset@aphp.fr.
LA  - fre
PT  - Journal Article
PT  - Observational Study
TT  - Prevalence des effets indesirables de l'hydroxychloroquine (Plaquenil((R))) dans 
      une population dermatologique : etude retrospective sur 102 patients.
DEP - 20180520
PL  - France
TA  - Ann Dermatol Venereol
JT  - Annales de dermatologie et de venereologie
JID - 7702013
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Hydroxychloroquine/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Skin Diseases/*drug therapy
MH  - Young Adult
OTO - NOTNLM
OT  - Drug-related adverse effects
OT  - Effets indesirables
OT  - Hydroxychloroquine
OT  - Imputability
OT  - Imputabilite
OT  - Tolerance
OT  - Tolerance
EDAT- 2018/05/25 06:00
MHDA- 2019/01/25 06:00
CRDT- 2018/05/25 06:00
PHST- 2017/10/27 00:00 [received]
PHST- 2018/01/23 00:00 [revised]
PHST- 2018/03/09 00:00 [accepted]
PHST- 2018/05/25 06:00 [pubmed]
PHST- 2019/01/25 06:00 [medline]
PHST- 2018/05/25 06:00 [entrez]
AID - S0151-9638(18)30416-2 [pii]
AID - 10.1016/j.annder.2018.03.168 [doi]
PST - ppublish
SO  - Ann Dermatol Venereol. 2018 Jun-Jul;145(6-7):395-404. doi: 
      10.1016/j.annder.2018.03.168. Epub 2018 May 20.